日本全国性研究:合并间质性肺炎肺癌的驱动基因检测与靶向治疗
该多中心回顾性研究纳入日本37家机构1256例晚期或复发NSCLC合并慢性纤维化间质性肺炎患者,分析基因检测现状、致癌驱动基因频率及靶向治疗的安全性和疗效。结果显示多基因检测使用不足(41.0%),KRAS突变最常见,靶向治疗组总生存最长,但部分靶向药物肺炎风险高。
要点
- 合并间质性肺炎的NSCLC患者多基因检测使用率低,仅41.0%。
- 多基因检测人群中KRAS突变最常见(4.7%),其次为EGFR(2.9%)。
- 接受靶向治疗的可靶向驱动基因患者总生存最长(中位39.2个月)。
核心结论
- 合并间质性肺炎的NSCLC患者多基因检测使用不足,但识别并治疗可靶向驱动基因可能改善生存。
- 多种靶向治疗携带较高肺炎风险,sotorasib相对安全。
研究设计与样本
- 多中心回顾性研究,纳入日本37家机构的1256例晚期或复发NSCLC合并慢性纤维化间质性肺炎患者(注册号UMIN000055609)。
主要发现
- 任何基因检测率为59.2%(95%CI 56.5-62.0),多基因检测仅41.0%(95%CI 38.3-43.8)。
- 多基因检测患者(N=515)中最常见突变为KRAS(4.7%;G12C 1.9%),其次EGFR(2.9%)、BRAF V600E(1.6%)、MET外显子14跳跃(1.6%)。
- 药物性肺炎发生率:sotorasib 0%(0/6),osimertinib 50%(4/8),alectinib 33%(1/3),dabrafenib联合trametinib及tepotinib均为25%(1/4)。
- 接受靶向治疗的可靶向驱动基因患者、未接受靶向治疗者、驱动基因阴性/未知患者的中位总生存分别为39.2、24.0和13.8个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Non-small cell lung cancer (NSCLC) patients with comorbid interstitial pneumonia (IP) are at high risk for drug-induced pneumonitis, and previous reports suggest a lower frequency of common driver mutations such as EGFR. This may discourage genetic testing, potentially overlooking prevalent, targetable mutations like KRAS, BRAF, and MET. This study aimed to elucidate the real-world status of genetic testing, the frequency of oncogenic drivers, and the safety and efficacy of targeted therapies in patients with NSCLC and comorbid IP. METHODS: This multicenter, retrospective study analyzed 1256 patients with advanced or recurrent NSCLC and comorbid chronic fibrosing IP from 37 Japanese institutions (Registry number: UMIN000055609). RESULTS: The rate of any genetic testing was 59.2 % (95 % confidence interval [CI], 56.5-62.0), with multigene testing performed in only 41.0 % (95 %CI, 38.3-43.8). Among patients with NSCLC undergoing multigene testing (N = 515), the most frequent mutations were KRAS (4.7 %; G12C, 1.9 %), followed by EGFR (2.9 %), BRAF V600E (1.6 %), and MET exon 14 skipping (1.6 %). The incidence of drug-induced pneumonitis was 0 % (0/6) for sotorasib, 50 % (4/8) for osimertinib, 33 % (1/3) for alectinib, and 25 % (1/4) for both dabrafenib plus trametinib and tepotinib. Patients with actionable oncogenic drivers receiving targeted therapy had the longest overall survival, followed by those not receiving it, and then driver-negative/unknown patients (median: 39.2, 24.0, and 13.8 months, respectively). CONCLUSIONS: Multigene testing is underutilized in this population. While many targeted therapies carry a high risk of pneumonitis, sotorasib appeared relatively safe. Despite the risks, identifying and treating actionable oncogenic drivers may improve survival.
引用
- Ikeda S, Ogura T, Misumi T, et al. Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan. Eur J Cancer. 2026. PMID: 41539179. doi:10.1016/j.ejca.2026.116232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。